Douglas A. Mata, MD, MPH

img_8978_180x140_2.jpg

Douglas A. Mata, MD, MPH, is an anatomic and clinical pathologist who trained as a resident physician at the Brigham and Women’s Hospital, as a clinical fellow at Harvard Medical School, and as molecular genetic pathology fellow at Memorial Sloan Kettering Cancer Center. He received his bachelor’s degree in biochemistry from Rice University, his medical degree from Baylor College of Medicine, and his master's degree in public health from the University of Cambridge. He was also a Fulbright Scholar at the European campus of the M.D. Anderson Cancer Center in Madrid, Spain. Dr. Mata currently serves as a non-resident tutor in pre-medicine at Dunster House, Harvard College.

His letters, editorials, and original research have appeared in New England Journal of MedicineJournal of the American Medical Association, Journal of Surgical Oncology, Lancet Psychiatry, and Proceedings of the National Academy of Sciences, and his work has been featured in Newsweek, New York TimesTime Magazine, U.S. News & World Report, and the Washington Post.

Follow him on Twitter @DouglasMataMD.

Recent Publications

2024

Kerr D, Cloutier J, Margolis M, Mata D, Rodrigues Simoes N, Faquin W, Dias-Santagata D, Chopra S, Charville G, Wangsiricharoen S, et al. GLI1-Altered Mesenchymal Tumors With ACTB or PTCH1 Fusion: A Molecular and Clinicopathologic Analysis. Mod Pathol. 2024;37(2):100386. doi:10.1016/j.modpat.2023.100386
Kerr D, Cloutier J, Margolis M, Mata D, Rodrigues Simoes N, Faquin W, Dias-Santagata D, Chopra S, Charville G, Wangsiricharoen S, et al. GLI1-Altered Mesenchymal Tumors With ACTB or PTCH1 Fusion: A Molecular and Clinicopathologic Analysis. Mod Pathol. 2024;37(2):100386. doi:10.1016/j.modpat.2023.100386
Williams E, Vegas I, El-Senduny F, Zhang J, Mata D, Hiemenz M, Hughes S, Sa B, Kraft G, Gorbatov N, et al. Pan-cancer Genomic Analysis of AXL Mutations Reveals a Novel, Recurrent, Functionally Activating AXL W451C Alteration Specific to Myxofibrosarcoma. Am J Surg Pathol. 2024. doi:10.1097/PAS.0000000000002191
Williams E, Vegas I, El-Senduny F, Zhang J, Mata D, Hiemenz M, Hughes S, Sa B, Kraft G, Gorbatov N, et al. Pan-cancer Genomic Analysis of AXL Mutations Reveals a Novel, Recurrent, Functionally Activating AXL W451C Alteration Specific to Myxofibrosarcoma. Am J Surg Pathol. 2024. doi:10.1097/PAS.0000000000002191
Mata D, Lee J, Shanmugam V, Marcus C, Schrock A, Williams E, Ritterhouse L, Hickman R, Janovitz T, Patel N, et al. Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results. Histopathology. 2024. doi:10.1111/his.15168
Mata D, Lee J, Shanmugam V, Marcus C, Schrock A, Williams E, Ritterhouse L, Hickman R, Janovitz T, Patel N, et al. Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results. Histopathology. 2024. doi:10.1111/his.15168

2023

Grube V, Narla S, Mata D, Hafeez F. Comparing Follicular Extension Between Low-Grade and High-Grade Dysplastic Nevi. Am J Dermatopathol. 2023;45(6):423–424. doi:10.1097/DAD.0000000000002438
Grube V, Narla S, Mata D, Hafeez F. Comparing Follicular Extension Between Low-Grade and High-Grade Dysplastic Nevi. Am J Dermatopathol. 2023;45(6):423–424. doi:10.1097/DAD.0000000000002438
Torre M, Bukhari H, Nithianandam V, Zanella C, Mata D, Feany M. A Drosophila model relevant to chemotherapy-related cognitive impairment. Sci Rep. 2023;13(1):19290. doi:10.1038/s41598-023-46616-9
Torre M, Bukhari H, Nithianandam V, Zanella C, Mata D, Feany M. A Drosophila model relevant to chemotherapy-related cognitive impairment. Sci Rep. 2023;13(1):19290. doi:10.1038/s41598-023-46616-9
Williams E, Ravindranathan A, Gupta R, Stevers N, Suwala A, Hong C, Kim S, Yuan JB, Wu J, Barreto J, et al. Novel SOX10 indel mutations drive schwannomas through impaired transactivation of myelination gene programs. Neuro Oncol. 2023;25(12):2221–2236. doi:10.1093/neuonc/noad121
Williams E, Ravindranathan A, Gupta R, Stevers N, Suwala A, Hong C, Kim S, Yuan JB, Wu J, Barreto J, et al. Novel SOX10 indel mutations drive schwannomas through impaired transactivation of myelination gene programs. Neuro Oncol. 2023;25(12):2221–2236. doi:10.1093/neuonc/noad121